PRP vs Exosomes for Hair Loss: How Each Works
How do PRP and exosome therapy work differently to stimulate hair growth?
Both syringes look the same going into the scalp, but they're carrying two different kinds of message. PRP hands the follicle a burst of free signaling proteins that knock on receptors from the outside, while a vesicle preparation can slip regulatory RNA inside the cell and change what that cell builds. Once you see that delivery difference, everything else about dose, consistency and evidence falls out of it.
| Criteria | PRP | Exosome preparation |
|---|---|---|
| Source | Patient's own blood, same visit | Donor cells expanded in culture |
| Active cargo | Free growth factors from alpha granules | microRNA, mRNA and proteins in a bilayer |
| Entry route | Receptor binding at the cell surface | Endocytosis or membrane fusion |
| Dose consistency | 3x to 6x whole-blood platelets, patient dependent | Stated particle count per lot |
| Human evidence | A decade of small randomized trials | Mostly cell culture and animal work |
PRP delivers a single burst of free growth factors that bind receptors on the outside of a dermal papilla cell, while exosomes are 30 to 150 nanometer vesicles that can fuse with that cell and release regulatory RNA inside it.
What growth factors do platelets release once PRP is activated in the scalp?
Nothing in a platelet gets made to order. The proteins are already packed into the alpha granules before you draw the blood, and once degranulation starts you've got minutes, not days, before most of that payload is spent. That's why a course of PRP is a series of pulses on a monthly rhythm instead of one loading dose.
- Alpha granule payload: PDGF, VEGF, EGF, TGF-beta 1, IGF-1, FGF-2 and FGF-7.
- Release window: Most of the stored protein is gone within the first hour.
- Working concentration: Three to six times whole-blood platelet count, dose response non-linear.
- Leukocyte content: Leukocyte-poor preparations are preferred for the cosmetic scalp bed.
Platelet alpha granules release seven pre-stored growth factors on activation, including the keratinocyte growth factor FGF-7, and the large majority of that payload is out within the first hour, which is why protocols repeat monthly rather than relying on one session.
What molecular cargo do exosomes carry and how is it different from a platelet growth factor payload?
A growth factor is a shout across the room; a vesicle is a sealed envelope handed to the person you want reading it. That isn't poetry, it's mechanism: free proteins have to find a receptor on the outside of the cell, while a membrane-bound package can unload short regulatory RNA into the cytoplasm and change which proteins that cell makes at all.
| Property | Platelet payload | Secreted vesicle |
|---|---|---|
| Physical form | Free proteins in solution | 30 to 150 nm lipid bilayer package |
| Cargo | Growth factor proteins only | microRNA, mRNA, transcription factors, lipids |
| Point of action | Receptor on the cell surface | Inside the cytoplasm |
| Survival in the dermis | Exposed to proteases, clears quickly | Membrane shields contents until docking |
An exosome carries microRNA, messenger RNA, transcription factors and surface tetraspanins such as CD9, CD63 and CD81 inside a protective bilayer, so it can adjust which genes a dermal papilla cell expresses rather than only firing a receptor on its surface.
How does each preparation actually deliver its signal into dermal papilla cells?
Here's where practitioners lose the thread: the mechanism everyone argues about only happens after the injectate lands, and neither preparation has any targeting whatsoever. What you inject goes where the needle put it and diffuses a limited distance, so your depth does more work than the biology does.
- Placement: The needle deposits material a few millimeters down, at the level of the bulge and bulb.
- Diffusion: Both preparations spread a short distance through interstitial fluid with no targeting of their own.
- Contact: A growth factor dimerizes a receptor tyrosine kinase; a vesicle engages integrins and tetraspanin domains.
- Entry: The protein relays its message across the membrane, while the vesicle crosses it by endocytosis or fusion.
- Loss: Much of the dose is bound by the wrong cells, degraded by dermal proteases, or carried off by the microcirculation.
A growth factor never crosses the cell membrane and relays its signal through receptor dimerization into PI3K/Akt, MAPK and Wnt/beta-catenin cascades, while a vesicle crosses that membrane outright by endocytosis or fusion and releases its RNA directly into the cytoplasm.
Which phase of the hair growth cycle does each therapy act on?
Neither therapy grows hair. Both are attempts to push a follicle across a phase boundary it would otherwise cross late or not at all, and in androgenetic alopecia that boundary keeps drifting the wrong way as each successive anagen shortens. Say that to your patient early, because it also explains why nothing looks different for the first few months.
Both PRP and vesicle preparations act at the telogen to anagen transition by tilting Wnt/beta-catenin signaling in the dermal papilla toward activation, and neither changes the androgen sensitivity driving miniaturization, so the effect holds only while maintenance sessions continue.
Why does an autologous blood product behave differently from a donor-derived cell product?
Autologous and allogeneic aren't two flavors of the same thing; each trades one set of problems for another. Your patient's own blood removes donor screening, transmissible disease risk and immune recognition in a single move, and hands you a dose that's only ever as good as they are that morning.
An autologous preparation carries no donor screening, transmissible disease or immune recognition risk but inherits the patient's platelet count, medication and age on the day of the draw, while a donor-derived lot removes that patient variability and takes on sourcing, cold chain and residual culture-media considerations instead.
How much of the result comes from the needle itself rather than the injected material?
This is the part the marketing on both sides would rather skip. Puncturing the dermis isn't a neutral act of delivery, it's an intervention on its own, and microneedling with nothing injected has produced measurable hair count gains in controlled trials. By the time you've made twenty to sixty passes across a thinning crown, you've already treated the patient before anything in the syringe counts.
- Wound cascade: Needle tracks trigger platelet aggregation, endogenous growth factor release and collagen remodeling.
- Missing control arm: Needled-saline arms are rare in the literature, so the split stays unmeasured.
- Drifting dose: Injection point count, gauge, depth and spacing vary between practitioners and between sessions.
Microneedling alone has produced measurable hair count improvement in controlled trials of androgenetic alopecia through the same Wnt and beta-catenin activation both injectable therapies claim, so any stated percentage split between the needle and the payload is invented rather than measured.
Why does PRP potency vary between patients while vesicle batches are standardized?
Variability in PRP is structural, not sloppiness. You're manufacturing every dose on the spot out of a raw material you didn't get to choose, then stacking your own spin protocol and buffy-coat draw-off on top of it.
| Dose variable | PRP | Manufactured vesicle lot |
|---|---|---|
| Starting material | Patient's blood, 150,000 to 400,000 platelets per microliter | Screened donor tissue expanded in culture |
| Final dose measured | Almost never | Particle count per mL on a certificate of analysis |
| Spread between patients | Threefold or more in one afternoon | Identical within a lot |
| Potency established | No | No, since particle count isn't potency |
Baseline platelet counts span roughly 150,000 to 400,000 per microliter before processing adds its own variation, so two patients treated the same afternoon by the same clinician can receive doses differing by a factor of three or more, while a manufactured lot delivers a precisely known particle count of something with no agreed potency assay behind it.
What does the published evidence actually establish about each mechanism?
Don't let a patient leave thinking these two sit on the same shelf of evidence, because conflating them is the most common error in consumer-facing material. One has a decade of small controlled trials and pooled analysis behind it, and the other rests largely on dishes and mice.
Pooled analysis of six controlled studies has reported a mean increase of about eighteen hairs per square centimeter for PRP over placebo with a confidence interval spanning roughly six to thirty, while no randomized trial comparing PRP, vesicle and needled-saline arms with blinded trichoscopic endpoints at twelve months has been published.
How does the regulatory status of each product shape what practitioners can offer?
The line between these two therapies is drawn on process, not on biology. Blood you draw, spin and reinject into the same patient in the same visit generally satisfies the minimal manipulation, homologous use and single-procedure criteria, so what you're offering is a procedure rather than an approved product. Donor cells expanded in culture, their vesicles isolated, formulated and cryopreserved, fail several of those criteria at once, and no such product holds a licence for hair restoration.
- Quality assurance: Sits with the supplier rather than with a licensing review.
- Claims: Presenting an unapproved biologic as an established treatment is the conduct regulators have acted on.
- Consent: Has to state plainly that the product isn't approved for this use and the human evidence is preliminary.
- Jurisdiction: Availability abroad under a different framework isn't evidence of approval at home.
PRP generally qualifies as a same-visit autologous procedure under the minimal manipulation and homologous use criteria, while a culture-expanded donor vesicle product is an unlicensed allogeneic biologic with no approval for hair restoration, so informed consent has to carry that unapproved status and the preliminary state of the human evidence.
